A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
Clin Cancer Res
; 29(6): 1017-1030, 2023 03 14.
Article
in En
| MEDLINE
| ID: mdl-36638198
Full text:
1
Database:
MEDLINE
Main subject:
Rectal Neoplasms
/
Colorectal Neoplasms
/
Colonic Neoplasms
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2023
Type:
Article
Affiliation country:
Australia